Although Redx has only been in operation since late-2010, it has already created several valuable drug candidates that are about to begin clinical development. Progress into the clinic will enhance significantly the value of these drug candidates as well as providing further technical validation of the company’s approach. Redx recently announced that its porcupine inhibitor (RXC004) has a potential role in cancer immunotherapy. Redx has now confirmed that RXC004 enhances the effect of a PD-1 checkpoint inhibitor in animal studies.
